Temporal genomic analysis of melanoma rejection identifies regulators of tumor immune evasion
Sapir Cohen ShvefeliD, Joy A. PaiiD, Yingying CaoiD, Lipika R. PaliD, Osnat BartokiD, Ronen LevyiD, Marie J. ZemanekiD, Chen WelleriD, Ella HerzogiD, Winnie YaoiD, Kamir J. Hiam-GalveziD, Kuoyuan ChengiD, Yajie YiniD, Peter P. DuiD, Colin J. RaposoiD, Nofar GumpertiD, Michèle WeltiiD, Julia M. Martínez GómeziD, Federica SellaiD, Elizabeta YakubovichiD, Irit OrriD, Shifra Ben‐DoriD, Roni OreniD, Liat Fellus-AlyagoriD, Ofra GolaniiD, , Yardena SamuelsiD
Abstract
Decreased intra-tumor heterogeneity (ITH) correlates with increased patient survival and immunotherapy response. However, even highly homogenous tumors may display variability in their aggressiveness, and how immunologic-factors impinge on their aggressiveness remains understudied. Here we studied the mechanisms responsible for the immune-escape of murine tumors with low ITH. We compared the temporal growth of homogeneous, genetically-similar single-cell clones that are rejected vs. those that are not- rejected after transplantation in-vivo using single-cell RNA sequencing and immunophenotyping. Non- rejected clones showed high infiltration of tumor-associated-macrophages (TAMs), lower T-cell infiltration, and increased T-cell exhaustion compared to rejected clones. Comparative analysis of rejection- associated gene expression programs, combined with in-vivo CRISPR knockout screens of candidate mediators, identified Mif (macrophage migration inhibitory factor) as a regulator of immune rejection. Mif knockout led to smaller tumors and reversed non-rejection-associated immune composition, particularly, leading to the reduction of immunosuppressive macrophage infiltration. Finally, we validated these results in melanoma patient data. Statement of significanceHere, we uncover the association of Mif expression with tumor growth and aggressiveness, specifically in low ITH tumors. These findings could facilitate the development of new strategies to treat patients with homogeneous, high-MIF expressing tumors that are unresponsive to immune checkpoint therapy.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 21
- FWCI
- 3.58
- Field percentile
- top 5%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- High immune receptor clonality in melanoma-draining lymph nodes associates with immune dysfunction and poor survival
Vincent P. Walter, Johanna Herold, … Lukas Flatz·bioRxiv·Jun 10, 2026
- CD244 regulates both innate and adaptive immune axes in melanoma by inhibiting autophagy-mediated M1 macrophage maturation
- The initial melanoma T cell infiltrate is defined by tissue-resident programs restrained by regulatory T cells
Jason B. Williams, Shishir Mani Pant, … Thomas Seth Kupper·bioRxiv·Oct 21, 2025
- Spatial polarization of endothelial ICAM-1 governs T-cell exclusion in melanoma
Ha-Ram Park, S. C. Kim, … Minah Kim·bioRxiv·Mar 23, 2026
- Melanoma clonal subline analysis uncovers heterogeneity-driven immunotherapy resistance mechanisms
C. Gruen, H. H. Yang, … E. Perez-Guijarro·bioRxiv·Apr 3, 2023
- MHC-I downregulation is associated with immune-evasion in breast cancers with heterogeneous activation of epithelial-mesenchymal plasticity
Kimaya M. Bakhle, Andreas Stephanou, … Anushka Dongre·bioRxiv·Oct 19, 2026